https://scholars.lib.ntu.edu.tw/handle/123456789/468855
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | SHANG-YI HUANG | en_US |
dc.contributor.author | CHUNG-WU LIN | en_US |
dc.contributor.author | Lin H.-H. | en_US |
dc.contributor.author | MING YAO | en_US |
dc.contributor.author | JIH-LUH TANG | en_US |
dc.contributor.author | SHANG-JU WU | en_US |
dc.contributor.author | YAO-CHANG CHEN | en_US |
dc.contributor.author | Lu H.-Y. | en_US |
dc.contributor.author | HSIN-AN HOU | en_US |
dc.contributor.author | Chen, Chien-Yuan | en_US |
dc.contributor.author | WEN-CHIEN CHOU | en_US |
dc.contributor.author | WOEI TSAY | en_US |
dc.contributor.author | Chou S.-J. | en_US |
dc.contributor.author | HWEI-FANG TIEN | en_US |
dc.creator | Huang S.-Y.;Chung-Wu Lin;Lin H.-H.;Yao M.;Tang J.-L.;Wu S.-J.;Chen Y.-C.;Lu H.-Y.;Hou H.-A.;Chen C.-Y.;Chou W.-C.;Tsay W.;Chou S.-J.;Tien H.-F. | - |
dc.date.accessioned | 2020-03-03T03:36:44Z | - |
dc.date.available | 2020-03-03T03:36:44Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 0939-5555 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84904762842&doi=10.1007%2fs00277-014-2063-7&partnerID=40&md5=04cb272decc8b33a46f385f133196aff | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/468855 | - |
dc.description.abstract | Cereblon (CRBN) is essential for the anti-myeloma (MM) activity of immunomodulatory drugs (IMiDs), such as thalidomide and lenalidomide. However, the clinical implications of CRBN in MM patients are unclear. Using immunohistochemical (IHC) staining on paraffin-embedded bone marrow sections, the expression of CRBN protein in myeloma cells (MCs) was assessed in 40 relapsed/refractory MM (RRMM) patients who received lenalidomide/dexamethasone (LD) and 45 and 22 newly diagnosed MM (NDMM) patients who received thalidomide/dexamethasone (TD) and melphalan/bortezomib/prednisolone (MVP), respectively. IHC staining were scored on a scale representing the diffuseness and intensity of positive-staining MCs (range, 0-8) and a score ?4.5 was used for CRBN positivity (CRBN+) on a cut-point analysis of all possible scores and response of TD and LD. Compared to CRBN+ NDMM patients, CRBN- NDMM patients had more international staging system (ISS) III (26 vs. 61 %, respectively; P=0.006). In the LD and TD cohorts, the response rate (RR) was higher in CRBN+ patients than CRBN- patients (LD 79 vs. 33 %, respectively; P=0.005) (TD 75 vs. 29 %, respectively; P=0.005); however, this trend was not observed in the MVP cohort. In the LD and TD cohorts, the positive and negative prediction value of CRBN+ for treatment response was 79 and 67 % and 75 and 71 %, respectively. Multivariate analysis showed that CRBN+ was a significant factor associated with superior RR for LD and TD. The data suggest that expression of CRBN protein in MCs assessed using the IHC is a feasible approach to predict the response of IMiDs in MM patients. ? 2014 The Author(s). | - |
dc.publisher | Springer Verlag | - |
dc.relation.ispartof | Annals of Hematology | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | bortezomib; cereblon; dexamethasone; lenalidomide; melphalan; prednisolone; protein derivative; thalidomide; unclassified drug; adult; aged; article; cancer prognosis; female; human; immunohistochemistry; major clinical study; male; middle aged; multiple myeloma; myeloma cell; overall survival; priority journal; progression free survival; protein expression; treatment response; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Boronic Acids; Dexamethasone; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplastic Stem Cells; Paraffin Embedding; Peptide Hydrolases; Prednisolone; Pyrazines; Salvage Therapy; Survival Analysis; Syndecan-1; Thalidomide; Treatment Outcome | - |
dc.title | Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1007/s00277-014-2063-7 | - |
dc.identifier.pmid | 24687382 | - |
dc.identifier.scopus | 2-s2.0-84904762842 | - |
dc.relation.pages | 1371-1380 | - |
dc.relation.journalvolume | 93 | - |
dc.relation.journalissue | 8 | - |
item.openairetype | journal article | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Pathology | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Integrated Diagnostics and Therapeutics-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Laboratory Medicine | - |
crisitem.author.dept | Laboratory Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Laboratory Medicine | - |
crisitem.author.dept | Laboratory Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.orcid | 0000-0001-5688-3410 | - |
crisitem.author.orcid | 0000-0001-5042-0503 | - |
crisitem.author.orcid | 0000-0003-2932-0019 | - |
crisitem.author.orcid | 0000-0003-4021-3281 | - |
crisitem.author.orcid | 0000-0002-0772-869X | - |
crisitem.author.orcid | 0000-0003-2780-4845 | - |
crisitem.author.orcid | 0000-0003-2831-8822 | - |
crisitem.author.orcid | 0000-0003-2967-698X | - |
crisitem.author.orcid | 0000-0001-6244-3868 | - |
crisitem.author.orcid | 0000-0002-1384-5593 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 病理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。